Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Posts Dip in Q2 Revenues, Greater R&D Spending, Widened Net Loss

NEW YORK, July 31 - Lexicon Genetics today reported a slight decrease in second-quarter revenues atop a mild increase in R&D spending and a widened net loss.

 

Total revenue for the period ended June 30 slipped to $8.9 million from $9.4 million one year ago. The revenue reflected a decrease in receipts from subscription and license fees, which shrank to $4.3 million from $5 million in the second quarter 2002, and a jump in income from collaborative research, which grew to $4.6 million from $4.3million year over year.

 

Second-quarter R&D spending grew nine percent, to $20.8 million from $19 million in the year-ago period, Lexicon said. The firm stressed that the increase reflected greater spending in drug-discovery programs.

 

As a result, net loss widened to $17.6 million, or $.34 per share, from $14.9 million, or $.29 per share, in the second quarter 2002.

 

Lexicon said it had around $95.6 million in cash and investments.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.